CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
|Articles|February 8, 2023
- BioPharm International's BP Elements, March 2023
- Volume 2
- Issue 3
iotaSciences Launches Single-Cell Picker
Author(s)BioPharm International Editors
iotaSciences isoPick is designed to expand handling solutions for cell biology and gene therapy applications.
Advertisement
iotaSciences, a spin-out from Oxford University specializing in single-cell handling solutions, announced completion of its new single-cell picker instrument on Feb. 6, 2023. The isoPick is designed to provide temperature-controlled handling of single cells during isolation, as well as picking through a workflow guided by touchscreen interfaces.
According to a company press release, the isoPick is intended for cell and gene therapy researchers, as well as the wider single-cell research community, as a means of providing verifiable isolation of single cells with high cell viability and stable single-cell outgrowth. Like the company's other instruments, it is designed to have a small footprint instrument that requires minimal maintenance.
Source:
Articles in this issue
over 3 years ago
Evolutions in Vaccine Developmentover 3 years ago
Advances in In Vivo CAR T-cell Therapiesover 3 years ago
FDA Issues Guidance on Potency for mAbs and Therapeutic Proteinsover 3 years ago
Charles River Launches Novel IgY-based ELISA KitAdvertisement
Related to this article
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Advertisement
Advertisement